Role of ketanserin in the treatment of the essential arterial hypertension associated with ischemic heart disease.
This clinical study was set-up to evaluate the antihypertensive effect of ketanserin in essential hypertension (EH) associated with asymptomatic ischemic heart disease (IHD) in twenty-seven patients. Every patient received 20-40 mg ketanserin, a selective S2 serotoninergic antagonist, twice daily, for a three-month period. The blood pressure (BP) was significantly lowered during the treatment with ketanserin, much more in female patients and elderly group.
Third Medical Clinic, Institute of Medicine, Tărgu-Mureş, Romania.
D
D
Podoleanu
S
S
Cotoi
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007650:Ketanserin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D012727:Sex Characteristics
D000959:Antihypertensive Agents; D012702:Serotonin Antagonists; D007650:Ketanserin